cyrilzakka/clinical-trials huggingface dataset:
Precision Preoperative Embolization of Pelvic Tumors to Improve Surgical Outcomes

The main purpose of this study is to assess the efficacy of precision preoperative embolization in decreasing operative blood loss, reducing surgical complications in pelvic tumor surgery. Furthermore the study aims at describing the vascularity in a series of pelvic tumors, and to correlate this with perioperative blood loss.

The main purpose of this study is to assess the efficacy of precision preoperative embolization in decreasing operative blood loss, reducing surgical complications in pelvic tumor surgery，which including poor wound healing，nerve injury，and pelvic organs dysfunction. Furthermore the study aims at describing the vascularity in a series of pelvic tumors,which contains four grade：poor，moderate，rich and abundant and to correlate this with perioperative blood loss.

Eligibility Criteria:
Inclusion Criteria:

* Primary or metastatic pelvic tumor
* Confirmed by contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) of the pelvic
* Planned surgical resection

Exclusion Criteria:

* Contrast medium allergy
* Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Alterations of Immunologic Mediators During Severe Sepsis

Severe sepsis induces significant changes in expression of insulin- and toll-like receptors, cytokines, markers of apoptosis, and activation of t- and b-lymphocytes.

In patients at early stage of severe sepsis, we investigate the expression of pro- and anti-inflammatory cytokines, chemokines, adhesion-molecules, toll-like receptors, insulin-receptors, markers of apoptosis und of t- and b-cell-activation on a mRNA level.

Eligibility Criteria:
Inclusion Criteria:

* age \>= 18 y
* agreement with study procedures
* 3 of 4 SIRS-criteria
* proven or highly suspected infection
* 2 or more sepsis-induced organ failures
* start of first sepsis-induced organ failure within the last 36 hours

Exclusion Criteria:

* non-agreement with study procedures
* signs of severe sepsis with organ failure \> 36 hours
* chronic immuno-compromising diseases
* chronic therapy with anti-inflammatory drugs
* non-curable cancer
* chronic renal failure with hemodialysis
* pregnancy or breast-feeding
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

This study will see if the researchers can lower that risk by giving the patient Palifermin. This drug helps protect the lining of the mouth, throat, and stomach. These areas typically get sores or ulcers while the blood cell counts are very low. The patient can get infections in or from these sores. Palifermin might also help the immune system recover faster. It is currently approved for patients who receive their own stem cells. That is called an autologous transplant. This study will test the use of Palifermin for T-cell depleted allogeneic stem cell transplants.


Eligibility Criteria:
Inclusion Criteria:

* Patients should be \< 65 years. Patients \> or equal to 65 years will be accrued on a case by case basis after discussion and approval by the BMT Service.
* Patients may be of either gender or any ethnic background.
* Patients must have a Karnofsky or Lansky Performance Status \> or equal to 70%.
* Patients must have adequate organ function measured by:

  \* Cardiac: asymptomatic or if symptomatic then LVEF at rest must be \> or equal to 50% and must improve with exercise.
* Hepatic: \< 3x ULN ALT and \< 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia.

  * Renal: serum creatinine \< than or equal to 1.2 mg/dl or if serum creatinine is outside the normal range, then CrCl \> 60-ml/min/1.73 m2
  * Pulmonary: asymptomatic or if symptomatic, DLCO \> 50% of predicted (corrected for hemoglobin)
* Each patient must be willing to participate as a research subject and must sign an informed consent form.
* Parent or legal guardians of patients who are minors will sign the informed consent form.

Exclusion Criteria:

* Active CNS or skin leukemic involvement
* Female patients who are pregnant or breast-feeding
* Active viral, bacterial or fungal infection
* Patient seropositive for HIV-I/II; HTLV -I/II
* Patients who have undergone a prior allogeneic or autologous stem cell transplant within the previous six months.
* Patients who have had a previous malignancy that is not in remission.
Data Collection of Demographics and Perioperative Care of Patients Undergoing Laparoscopic Surgery

The goal of this clinical research study is to collect information on patients who had or are going to have laparoscopy performed at M. D. Anderson. Researchers want to use this information to learn the effects of laparoscopic surgery on patients over time.

If you agree to take part in this study, your demographic information (such as your age, race, medical and surgical history, and type of cancer) will be collected. Information about the type of surgical procedure performed on you, your care during and after your surgery, any problems related to your surgery, and details about your follow-up care will be entered into a research database. This information will be collected from patients seen at M. D. Anderson since January 1, 1990. It will be used for future research studies.

The research database will be updated, after about 1 year, to include information on your disease outcome, treatment, and/or follow-up care. This information will be collected from your medical record, if possible. If it is not in your medical record, you may again be contacted so that researchers can learn this information.

Your participation in this study will continue up to 5 years after your laparoscopic procedure.

This is an investigational study. Up to 1,000 patients will take part in this study. All will be enrolled at M. D. Anderson.

Eligibility Criteria:
Inclusion Criteria:

1. All patients who had or will have laparoscopic surgery in the Department of Gynecologic Oncology (Gynecologic Oncology and General Gynecology) since January 1, 1990 forward.

Exclusion Criteria: None
Blue Protocol and Eko Artificial Intelligence Are Best (BEA-BEST)

This is an observational study that will be enrolling University of Louisville patients who present to the Emergency Department in Acute Respiratory Failure. This study will be to determine if the addition of Eko AI-assisted lung auscultation examination to a standard of care Pulmonary POCUS + assists with acute respiratory failure diagnosis.

Once identified and consented, the subject will undergo both POCUS and AI-assisted lung auscultation using an Eko CORE stethoscope. The POCUS protocol described here is the standard of care for patients who present in acute respiratory failure to the Emergency Room and both groups will receive this standardized care during the study.

Upon hospital discharge, the final discharge diagnosis will be used as the ground truth for assessing the accuracy of the POCUS protocol. The POCUS exam and the EkoAI exam may be performed wherever the subject is located in the hospital when first enrolled in the study. If possible, both exams should be performed immediately, in either order. They will be performed by the same examiner.

Both the POCUS and the EkoAI exam will be analysed by an investigator blinded to the final diagnosis.

Eligibility Criteria:
Inclusion Criteria:

* Adults aged 18 years or older presenting to the ED or admitted to the hospital within 12 hours of enrollment
* Acute respiratory failure defined as new onset shortness of breath initiated within the last 7 days, and new or increasing need for oxygen therapy
* The patient or patient's legal health care proxy consents to participation

Exclusion Criteria:

Unwillingness to consent

* Patients with trauma as the cause of ARF
* Patients with pneumothorax as the cause of ARF
* Inability to perform pulmonary POCUS or lung auscultation (e.g. dressing on the chest)
* Unwilling or unable to complete the minimum of 12 lung sound stethoscope recordings.
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure

This pragmatic clinical trial aims to evaluate the impact of a telemonitoring program with an electronic alert system compared to standard treatment on the perception of self-care in patients after hospitalization for decompensated HF at 3 months post-discharge. And secondarily to evaluate its impact on clinical events, NT-proBNP and efficacy and safety to facilitate the use and titration of the recommended drugs in patients with reduced ejection fraction at 90 days.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Hospitalized for acute heart failure (regardless of the level of left ventricular ejection fraction) within 24 hours of discharge, or with a history of hospitalization for acute HF within 10 days prior to randomization.
* Own a smartphone (Smartphone) with internet Ability to speak and read Spanish.
* Residence in the metropolitan area of Buenos Aires

Exclusion Criteria:

* Pregnancy
* Alcohol or drug abuse
* Kidney failure in hemodialysis,
* Inability to use the app (Ex: cognitive impairment, lack of social support, lack of ability to communicate)
* Active cancer
* Life expectancy less than 1 year
* Candidates for care home or institutional end of life
* Severe psychiatric illness
* Planned cardiac surgery
* Patient unable or unwilling to give informed consent to participate.
Influence of Age, Sepsis and SLCO1A2 Polymorphisms on Rocuronium Pharmacokinetics

This study aims to evaluate the influence of age and sepsis on in vivo activity of OATP1A2 using rocuronium (ROC) as a probe and evaluating the pharmacokinetics and pharmacodynamics in ASA I-III surgical patients. Thus, adult patients without sepsis (control group, n= 12), adult patients with sepsis (sepsis group, n= 12) and elderly patients without sepsis (elderly group, n= 12), all submitted to small to medium-sized surgeries who were induced with individual doses of rocuronium, fentanyl and propofol are being investigated.

Rocuronium (ROC), a neuromuscular blocking agent used in surgical procedures, is primarily eliminated by biliary excretion. Its distribution to the liver, mediated the organic anion transporting polypeptide 1A2 (OATP1A2), is a determining factor for the duration of neuromuscular blockade. Age and release of cytokines during inflammation and infection processes of sepsis can alter expression of SLCO1A2 gene, encoding OATP1A2. The objective of this study is to evaluate the influence of age and sepsis on in vivo activity of OATP1A2 using ROC as a probe and evaluating the pharmacokinetics and pharmacodynamics in ASA I-III surgical patients. Adult patients without sepsis (control group, n=12), adult patients with sepsis (sepsis group, n=12) and elderly patients without sepsis (elderly group, n=12), all submitted to small to medium-sized surgeries are being investigated. All patients are being induced with individual doses of rocuronium, fentanyl and propofol. Serial blood samples are being collected up to 360 minutes after administration of ROC. Neuromuscular blockade induced by ROC is monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same times of blood sampling. The plasma concentration of ROC will be analyzed by liquid chromatography coupled to mass spectrometry with electrospray ionization using positive ion mode.

Eligibility Criteria:
Inclusion Criteria:

* Adult and elderly patients, both gender.
* Patients submitted to small to medium-sized surgeries.
* Patients who were induced with individual doses of rocuronium, fentanyl and propofol.
* Patients with normal renal function (creatinine clearance \> 60 mL/min).
* Patients with normal liver function.

Exclusion Criteria:

* Patients who were in use of fluoxetine, carbamazepine, aminoglycoside antibiotics, OATP1A2 inhibitors.
* Patients with gastrointestinal and liver diseases, neuromuscular disorders.
* Patients who were in chronic use of drugs which alter rocuronium effect.
A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults

PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999 administered twice daily over 14 days. Exploratory measures of PDE2 inhibition will also be evaluated in blood and blister fluid.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male and/or female (of non-childbearing potential) subjects between the ages of 18 and 55 years
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs)

Exclusion Criteria:

* Subjects with Gilbert's disease or screening laboratory test results that deviate from the upper and/or lower limits of the reference or acceptable range. The exception is that all liver function tests must not exceed the upper limit of normal.
* Subjects with evidence of, or history of, hepatic disorder, including acute or chronic hepatitis B or hepatitis C.
* Subjects with very light skin or very dark skin (at the discretion of the investigator).
Examining the Effects of a Telehealth Self-management Intervention in Multiple Sclerosis

The objective of this study is to conduct a randomized controlled trial to examine the effectiveness of a telehealth intervention that supports individuals in managing fatigue and increasing physical activity (PA) behavior in individuals with multiple sclerosis (MS). The hypothesis is that a fatigue management plus physical activity intervention will significantly improve fatigue, quality of life, physical function, and community integration.

The long-term objective of this study is to use a telehealth intervention approach to reduce the devastating effects of the reciprocal relationship between fatigue and inactivity on quality of life and participation in life roles in people with multiple sclerosis (MS). Chronic fatigue and inactivity are common problems in persons with MS, and the reciprocal relationship between fatigue and inactivity may have negative synergistic effects on quality of life and participation in life roles. The proposed study is novel in that it represents a multi-disciplinary effort to merge two promising lines of MS research: fatigue management and PA promotion. The proposed fatigue management plus PA intervention (FM+) will consist of incorporating a modified teleconference version of Packer et al.'s empirically-tested Fatigue Management program with innovative, yet simple approaches to promote lifestyle PA by encouraging goal-setting and self-monitoring with a pedometer. Ambulatory individuals with MS will be recruited and randomized into one of three telehealth interventions: social support intervention, PA-only intervention, and FM+.

Eligibility Criteria:
Inclusion Criteria:

* A physician-confirmed diagnosis of MS

Exclusion Criteria:

* Exercise more than 90 minutes per week
* Pregnant
* Metabolic or cardiopulmonary disease that puts patient at high risk for engaging in a home exercise program (patients with controlled diabetes and high blood pressure will still be considered eligible)
* Four or more falls in the past 6 months
* Be able to walk 25 feet with or without a cane or walker
* Severe cognitive deficits
* A condition besides MS that had lead to hospitalization in the past year
Analysis of Topographic Corneal Parameters

The Pentacam HR system (OCULUS) has been suggested to be one of the most sensitive instruments for corneal examination before corneal refractive surgery

Retrospective non randomized study Analysis of different corneal paremeters obtained by Pentacam for corneal refractive surgery candidates during last 3 years from both sexes between 18 and 45 years K1 - K2 - K max - Pachymetry apex - Pachymetry thinnest - Distance between apex and thinnest - Back elevation - Topography shape - Keratoconus (If present)

Eligibility Criteria:
Inclusion Criteria:

* Persons from both sexes between 18 and 45 years seeking corneal refractive surgery

Exclusion Criteria:

* Previous intraocular surgery
* Previous corneal surgery
* Corneal opacity
AZD3293 Thorough QT Study in Healthy Male Volunteers

A thorough QT study of AZD3293

A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (moxifloxacin) as a Positive Control, in Healthy Male Subjects

Eligibility Criteria:
Inclusion Criteria:

1. Provision of signed, written and dated informed consent prior to any study-specific procedures
2. Healthy male subjects must be able to understand and be willing to comply with study procedures, restrictions and requirements
3. Healthy male subjects aged 18 to 55 years
4. Body weight ≥ 50 to ≤ 100 kg and body mass index (BMI) ≥19 to ≤30
5. Clinically normal findings on physical examination in relation to age, as judged by the investigator.

Exclusion Criteria:

1. History of any clinically significant disease or disorder which may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
2. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
3. History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder
4. History of neurologic disease, including seizures (with the exception of febrile infantile seizures), recent memory impairment or clinically significant head injury
5. History of psychotic disorder among first degree relatives
Heat Loss in Humans Covered With Full-Body Blankets Connected to Different Warming Devices

The investigators propose a single-center multiple crossover randomized trial to determine the efficacy of four warming devices and five warming blankets. The investigators will measure cutaneous heat loss/ gain using thermal flux transducers in unanesthetized volunteers.

The investigators propose a single-center, assessor-Blinded, multiple crossover randomized trial to determine the efficacy of four warming devices and five blankets. The investigators will measure cutaneous heat loss/ gain using thermal flux transducers in unanesthetized volunteers.

American Society of Anesthesiologists (ASA) physical status 1 and 2 adults with body-mass index 20-33 kg/m2 will be included in this study. Volunteers will be excluded if they have serious skin lesions, history of allergy or skin sensitivity to tape or adhesive materials, serious vascular disease in the arms including Raynaud's Syndrome, or a history of recent fever or infection.

20 volunteers will be randomized to one of 5 different sequence groups: 1. Mistral Air, Blower MA1200-PM. plus the Adult Blanket plus, MA2220, 2. Mistral Air, Blower MA1200-PM plus the Premium Adult Blanket, 3320, 3. 3M, Bair Hugger, Blower 775 plus Blanket full body, 30000, 4. Smiths Medical, Blower L1-CW-100V, plus Blanket full body SWU-2001, 5. Care Essential, Cocoon, Blower CWS5000 plus Blanket Full Body blanket (CLM0101).

Eligibility Criteria:
Inclusion Criteria:

* Body-mass index 20-33 kg/m2
* Age 18-40 yrs.
* ASA Physical Status 1-2.

Exclusion Criteria:

* Serious skin lesions
* History of allergy or skin sensitivity to tape or adhesive materials
* History of serious vascular disease in the arms, including Raynaud's Syndrome
* History of recent fever or infection
The Effect of Kegel Exercise in Nursing Students With Primary Dysmenorrhoea

In this study, it was aimed to determine the effect of kegel exercise on menstruation symptoms, severity of dysmenorrheic symptoms and quality of life in nursing students with primary dysmenorrhea. The study was conducted as a single-blind randomized controlled trial.

The study was conducted in a single-blind randomized controlled trial with 89 nursing students with primary dysmenorrhea. The experimental group was given kegel exercise training online, and after the training, a message was sent to remind them to do kegel exercises three times a day during the follow-up. No intervention was made in the control group.

Hypotheses of the Research

1. VAS total scores in interventions involving kegel exercise training and regular kegel exercise are lower than control interval rates (H1).
2. The total score of the Menstruation Symptom Scale within the participants who participated in kegel exercise training and regular kegel exercise was recorded, at lower rates than the distribution of control intervals (H1).
3. The Severity of Dysmenorrheic Symptoms in participants who participated in kegel exercise training and regular kegel exercise interventions were lower than the distribution of control intervals (H1).
4. The total scores of the Quality of Life Scale among those who participated in kegel exercise training and regular kegel exercises were higher than the proportions of the controlled rankings (H1).

Eligibility Criteria:
Inclusion Criteria:

* be between the ages of 18-25
* Giving 6 points or more to the least menstruation pain on the day that individuals experience the most severe dysmenorrhea symptoms (VAS) out of 10 points on the VAS Visual Pain Scale
* Being Nulliparous (never giving birth)
* Regular menstruation for the last six months
* Not having any gynecological diagnosis
* Not having had a gynecological operation
* Volunteering to participate in the study

Exclusion Criteria:

* Being a man
* Being married
* Being diagnosed with secondary dysmenorrhea
* Giving menstruation pain less than 6 points out of 10 on the VAS Visual Pain Scale.
* Taking painkillers 12 hours before the assessments.
The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers

Treatment of chronic pain is a major clinical challenge since chronic pain is frequent and leads to deterioration of quality of life. An injury or wound can lead to long term changes in the nervous system that make the skin more sensitive at and near the injury; this is termed hyperalgesia and occurs through long term depotentiation (LTP), i.e., a change in the synaptic interaction between neurons.

Opioids are the gold standard for the symptomatic therapy of moderate to severe pain. Now, in animal studies the investigators have discovered previously unrecognized effects of opioids.

UV-B irradaition of the skin of the thigh is an established model of priamary and secondary hyperalgeisa in humans. The investigators want to test the influence of remifentanil, an ultra-short acting opioid, on hyperalgesia observed after UV-B irradiation in human volunteers in a double blind cross-over prospective active placebo controlled clinical trial.


Eligibility Criteria:
Inclusion Criteria:

* Body mass index between 15th and 85th percentile
* Normal findings in the medical history and physical examination
* Drug free for 1 week prior to the study day

Exclusion Criteria:

* Regular use of medication especially analgesics
* Abuse of alcoholic beverages, drug abuse
* History of asthma
* Participation in a clinical trial in the 2 weeks preceding the study
* Symptoms of a clinically relevant illness in the 2 weeks before the first study day
* Resting systolic blood pressure \> 135 mmHg or diastolic blood pressure \> 85 mmHg
* Acute skin diseases like sunburn on the relevant areas or skin lesions
* Pregnancy or breast feeding
* UV sensitive skin conditions, like Xeroderma pigmentosa